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Abstract
This study focuses on exploring the expression of genes associated with depressive
and anxiety disorders (AD) among depressed individuals. Anxiety and depression are
well known to co-occur with each other. Growing research in the field of genetics has
indicated moderate familial aggregation for these disorders. The aim of this study is to
analyze gene expression among a depressed population residing in the UAE. The genes
chosen to be studied (PPARGC1A, CAMKMT, HSD11B1, SLC6A4 and MAOA) have
previously been linked to depression and anxiety in other populations. The study
employed a case-control design, where gene expression in blood samples of the
depressed group (29 participants) were compared with a control group (30
participants). Initial screening of depression levels for all participants was done using
the Beck Depression Inventory (BDI) and Patient Health Questionnaire – 9 (PHQ9),
and formal diagnosis for participants in the depression group was given by
psychiatrists using ICD-10 criteria. Results indicate that the expression of PPARGC1A
gene is significantly lower among the depressed group. These results indicate a novel
association of PPARGC1A with depression and open several possibilities for further
research to study its role as a protective factor against developing depression.
Keywords: Depression, anxiety, gene expression, PPARGC1A, HSD11B1, CAMKMT,
SLC6A4.
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)Title and Abstract (in Arabic

دراﺳﺔ اﻟﻌﻼﻣﺎت اﻟﺤﯿﻮﯾﺔ اﻟﻮراﺛﯿﺔ ﻟﻠﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﻌﺎﻧﻮن ﻣﻦ اﻻﻛﺘﺌﺎب ﻓﻲ دوﻟﺔ اﻻﻣﺎرات
اﻟﻌﺮﺑﯿﺔ اﻟﻤﺘﺤﺪة
اﻟﻤﻠﺨﺺ

ﺗﺮ ﻛ ﺰ ھ ﺬ ه اﻟﺪ ر اﺳ ﺔ ﻋ ﻠﻰ اﺳ ﺘﻜ ﺸ ﺎف اﻟﺘﻌ ﺒﯿﺮ ﻋ ﻦ اﻟﺠ ﯿﻨ ﺎ ت اﻟﻤ ﺮ ﺗﺒﻄ ﺔ ﺑ ﺎﺿ ﻄ ﺮ اﺑ ﺎ ت اﻻ ﻛ ﺘﺌ ﺎ ب
واﻟﻘﻠﻖ ) (ADﻓﻲ ﻋﯿّﻨﺔ ﻣﻦ اﻷﻓﺮاد اﻟﻤﺼﺎﺑﯿﻦ ﺑﺎﻻﻛﺘﺌﺎب .ﻣﻦ اﻟﻤﻌﺮوف ﺟﯿﺪًا أن اﻟﻘﻠﻖ واﻻﻛﺘﺌﺎب
ﯾﺤ ﺪ ﺛ ﺎن ﻣ ﻊ ﺑﻌ ﻀ ﮭ ﻤ ﺎ اﻟﺒﻌ ﺾ  ،و ﻗ ﺪ اﺷ ﺎر ت اﻟﺒﺤ ﻮ ث ﻓ ﻲ ﻣ ﺠ ﺎ ل ﻋ ﻠﻢ اﻟﻮ ر اﺛﺔ إﻟﻰ و ﺟ ﻮ د ﺗ ﻜ ﺪ س و ر ا ﺛ ﻲ
ﻋﺎﺋﻠﻲ ﻣﻌﺘﺪل ﻟﮭﺬه اﻻﺿﻄﺮاﺑﺎت .ﺗﮭﺪف ھﺬه اﻟﺪراﺳﺔ إﻟﻰ ﺗﺤﻠﯿﻞ اﻟﺘﻌﺒﯿﺮ اﻟﺠﯿﻨﻲ ﻓﻲ ﻋﯿّﻨﺔ ﻣﻦ
ا ﻟ ﻤ ﺼ ﺎ ﺑ ﯿ ﻦ ﺑ ﺎ ﻻ ﻛ ﺘ ﺌ ﺎ ب ا ﻟ ﻤ ﻘ ﯿ ﻤ ﯿ ﻦ ﻓ ﻲ د و ﻟﺔ اﻹ ﻣ ﺎر ا ت اﻟﻌ ﺮ ﺑﯿﺔ اﻟﻤ ﺘﺤ ﺪ ة .و ﻗ ﺪ ﺗ ﻢ ﻣ ﺴ ﺒﻘ ﺎ ر ﺑﻂ اﻟﺠ ﯿ ﻨ ﺎ ت اﻟﺘ ﻲ
ﺗﻢ اﺧﺘﯿﺎرھﺎ ﻓﻲ ھﺬه اﻟﺪراﺳﺔ )  SLC6A4 ،HSD11B1 ،CAMKMT ،PPARGC1Aو
 (MAOAﺑﺎﻻﻛﺘﺌﺎب واﻟﻘﻠﻖ ﻓﻲ ﻣﺠﻤﻮﻋﺎت أﺧﺮى .اﺳﺘﺨﺪﻣﺖ اﻟﺪراﺳﺔ ﺗﺼﻤﯿًﻤﺎ ﻟﻠﺘﺤﻜﻢ ﻓﻲ اﻟﺤﺎﻻت
 ،ﺣﯿﺚ ﺗﻤﺖ ﻣﻘﺎرﻧﺔ اﻟﺘﻌﺒﯿﺮ اﻟﺠﯿﻨﻲ ﻓﻲ ﻋﯿﻨﺎت اﻟﺪم ﻟﻼﺷﺨﺎص اﻟﻤﺼﺎﺑﯿﻦ اﻻﻛﺘﺌﺎب ) 29ﻣﺸﺎرًﻛﺎ(
ﻣﻊ اﻟﻤﺠﻤﻮﻋﺔ اﻟﻀﺎﺑﻄﮫ ) 30ﻣﺸﺎرًﻛﺎ( .ﺗﻢ اﻟﻔﺤﺺ اﻷوﻟﻲ ﻟﻤﺴﺘﻮﯾﺎت اﻻﻛﺘﺌﺎب ﻟﺠﻤﯿﻊ اﻟﻤﺸﺎرﻛﯿﻦ
ﺑﺎﺳﺘﺨﺪام اﺳﺘﺒﯿﺎن  (BDI)Beck Depression Inventoryواﺳﺘﺒﯿﺎن ﺻﺤﺔ اﻟﻤﺮﺿﻰ 9 -
) ، (PHQ9وﺗﻢ ﺗﻘﺪﯾﻢ اﻟﺘﺸﺨﯿﺺ اﻟﺮﺳﻤﻲ ﻟﻠﻤﺸﺎرﻛﯿﻦ ﻓﻲ ﻣﺠﻤﻮﻋﺔ اﻻﻛﺘﺌﺎب ﺑﻮاﺳﻄﺔ أطﺒﺎء ﻧﻔﺴﯿﯿﻦ
ﯾﺴﺘﺨﺪﻣﻮن ﻣﻌﺎﯾﯿﺮ  .ICD-10ﺗﺸﯿﺮ اﻟﻨﺘﺎﺋﺞ إﻟﻰ اﻧﺨﻔﺎض ﻧﺴﺒﺔ اﻟﺘﻌﺒﯿﺮ اﻟﺠﯿﻨﻲ ﻟـ  PPARGC1Aﻓﻲ
اﻻﻓﺮاد اﻟﻤﺼﺎﺑﯿﻦ ﺑﺎﻻﻛﺘﺌﺎب  .ﺗﺸﯿﺮ اﻟﻨﺘﺎﺋﺞ إﻟﻰ أن اﻟﺘﻌﺒﯿﺮ ﻋﻦ اﻟﺠﯿﻦ  PPARGC1Aھﻮ أﻗﻞ ﺑﻜﺜﯿﺮ
ﺑ ﯿ ﻦ ا ﻟ ﻤ ﺠ ﻤ ﻮ ﻋ ﺔ ا ﻻ ﻛ ﺘ ﺌ ﺎ ب  .ﻣ ﻘ ﺎر ﻧﺔ ﺑ ﺎﻟﻤ ﺠ ﻤ ﻮ ﻋ ﺔ اﻟﻀ ﺎﺑﻄ ﺔ  .ﺗﺸ ﯿﺮ ھ ﺬ ه اﻟﻨﺘ ﺎﺋﺞ ﺗﺸ ﯿﺮ إﻟ ﻰ و ﺟ ﻮ د ﻋ ﻼ ﻗﺔ
ﺟﺪﯾﺪة ﺑﯿﻦ  PPARGC1Aواﻻﻛﺘﺌﺎب وﺗﻔﺘﺢ اﻟﻌﺪﯾﺪ ﻣﻦ اﻻﺣﺘﻤﺎﻻت ﻟﻤﺰﯾﺪ ﻣﻦ اﻟﺒﺤﺚ ﻟﺪراﺳﺔ دورھﺎ
ﻛ ﻌ ﺎﻣ ﻞ و ﻗ ﺎﺋ ﻲ ﺿ ﺪ اﻻ ﻛ ﺘﺌ ﺎب .

ﻣﻔﺎھﯿﻢ اﻟﺒﺤﺚ اﻟﺮﺋﯿﺴﯿﺔ :اﻻﻛﺘﺌﺎب ،اﻟﻘﻠﻖ ،اﻟﺘﻌﺒﯿﺮ اﻟﺠﯿﻨﻲ،CAMKMT ، HSD11B1 ،
.SLC6A4
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Chapter 1: Introduction
1.1 Overview
1.1.1 Depressive Disorders
Depressive disorders are a group of disorders that are characterized by chronic
sadness, feelings of emptiness or irritable mood, along with changes in somatization
and cognitions (American Psychiatric Association, 2013). Individuals going through
these feelings and changes find it difficult to carry out daily functions. In 2004, the
World Health Organization (WHO) reported an estimated 151.2 million individuals to
be suffering from a unipolar depressive disorder, making it the most prevalent of
mental health conditions (World Health Organization, 2008). For the purposes of their
report, severe depression was classed together with active psychosis, severe migraine,
quadriplegia, and terminal stage cancer on the basis their disability. Unipolar
depressive disorders also accounted for the leading global cause of years lost due to
disability (YLD) in both sexes, and in all low-, middle-, and high-income countries. It
was also projected to rank first by 2030 in terms of potential years of healthy life lost
due to “being in states of poor health or disability” (World Health Organization, 2008).
The various risk factors leading to depression can broadly be categorized as
environmental factors and genetic factors. Environmental factors, particularly, abuse
and neglect in the childhood years are risk factors for various psychiatric symptoms
and disorders, but particularly so for mood and anxiety disorders (Heim, Shugart,
Craighead, & Nemeroff, 2010). However, 30-40% of the risk has been found to be
genetically determined (Heim & Binder, 2012).
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1.1.2 Anxiety Disorders
Anxiety disorders (AD) comprise of a group of disorders that share the
common features of excessive fear, anxiety and related behaviors in anticipation of
future threats. These include separation anxiety disorder, selective mutism,
agoraphobia, generalized anxiety disorder (GAD), social anxiety disorder (SAD),
panic disorder (PD) and specific phobia (SP). As opposed to fear, anxiety-related
behaviors are often associated with excessive attentiveness in preparation for possible
dangers, muscle tension and avoidance or caution (American Psychiatric Association,
2013).
Similar to depression, ADs are more prevalent in women - affecting twice the
number of women than men, and often have onset during childhood and adolescence.
In fact, individuals within the age range of 10-25 years have been found to be at the
highest risk for developing an AD, with more than a third of this population meeting
criteria for an AD (Nieto, Patriquin, Nielsen, & Kosten, 2016). Environmental factors
are known to be the leading causes of ADs as well. However, recent findings in the
field of genetic epidemiology show heritability to be in the range of 30-50%, indicating
moderate familial aggregation (Shimada-Sugimoto, Otowa & Hettema, 2015).
1.1.3 Comorbidity of Depression and Anxiety
Major depressive disorder has previously been found to be the most prevalent
of all mental health conditions. Though, when taken as a group, the prevalence of mood
disorders falls behind ADs (Merikangas et al., 2007). Depression and anxiety are
generally seen to co-occur with other psychiatric conditions such as substance use
disorders and personality disorders. However, depression comorbid with anxiety can
in fact be considered the norm rather than the exception in most clinical presentations
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of such disorders (Fava et al., 2008). More than half (57%) of the individuals suffering
from a depressive disorder have been found to have a comorbid anxiety disorder
(Zimmerman, McDermut, & Mattia, 2000). Anxiety can not only be seen as a
comorbidity, but also as a predominant feature of major depressive disorder in some
cases (Malhi & Mann, 2018). AD diagnoses in depressive disorders has also been
found to increase the likelihood of having suicidal thoughts as well as completed
suicide (Goldberg & Fawcett, 2012).
It was found a few decades ago that the comorbidity between depressive and
anxiety disorders is not due to chance, and that the occurrence of an affective disorder
increases the risk of having an AD and vice-versa (Kessler, 1995). Klein & Riso
(1993), and later Neale & Kendler (1995), developed models to explain the
comorbidity between these disorders. These models are referred to as KR1-KR11 and
NK1-NK12 respectively, all of which are outlined in Table 1 adopted from Neale &
Kendler (1995).
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Table 1: Klein & Riso and Neale & Kendler's models of comorbidity (Neale &
Kendler, 1995)
Model

Cause of comorbidity

KR1/NK1

Comorbidity due to chance

KR2/NK2

Comorbidity due to sampling bias

KR3/NK3

Comorbidity

due

to

population

stratification
KR4

Comorbidity

due

to

overlapping

diagnostic criteria
KR5

Comorbidity due to one disorder
encompassing the other

KR6

Comorbidity due to multiformity of
one disorder

KR7

Comorbidity due to heterogeneity

KR8/NK9

Comorbidity due to third independent
disorder

KR9/NK4

Comorbidity due to alternative forms
or phases

KR10/NK11

Comorbidity due to one disorder being
risk factor for the other

KR11/NK10

Comorbidity

due

to

overlapping

etiological processes
NK12

Comorbidity

due

to

reciprocal

causation

More recently, a review conducted by Middledorp et al. (2005) focusing on
twin studies and family studies found most of these models to fit the data (NK6, NK10,
NK11 and NK12). Among these models, NK11 (i.e., MDD causing GAD was found
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to be the best-fitting model). Their results also ruled out KR8/NK9 as a suitable model.
The authors consequently provided different plausible mechanisms for their findings.
The first mechanism explains the co-morbidity due to interconnections of different
brain regions that are responsible for generating different emotions and responses. The
second mechanism uses the heritability of neuroticism as a personality trait as an
explanation.
1.1.4 Mental Health in the Arab World
The gulf region has seen rapid change in sociodemographic factors over the
past four decades derived by the discovery of oil and the subsequent boost in economy.
These changes, which include a shift in family-life, food habits, social cohesion and
exercise (Osman & Afifi, 2010), and the drastic generation gap, are bound to cause
mental health challenges.
Even as early as in the 1990s, the WHO recommended spending not less than
10% of the country’s health care budget on mental health services, reserving 25% of
hospital beds for mentally ill patients, as well as having a ratio of 0.25-1.0 psychiatrists
for every 10,000 persons (World Health Organization, 1996). In a study published by
Okasha (1999), it was reported that the United Arab Emirates had only 30 hospital
beds allocated to psychiatric patients and one mental health hospital. There were 40
registered psychiatrists at the time, with a ratio of one psychiatrist per 62,500
individuals in the population. Apart from the psychiatrists, there were 13
psychologists, 30 social workers and 109 psychiatric nurses in the country. However,
in a large-scale survey published more than a decade later, the ratio of psychiatrists in
the UAE rose from 0.9 to 2 per 100,000 individuals, along with an increase in
psychologists and social workers (Okasha, Karam, & Okasha, 2012). This change was

6
also seen in almost all other Arab nations. Despite the increase in professionals, the
budget allocated by governments for mental health services was still found to be far
below the recommended amount.
In general, no nation-wide data is currently available on the prevalence of
depression in the U.A.E., both for citizens and residents. However, a large-scale study
conducted by Moselhy et al. (2012) found that approximately 18.7% of the Emirati
population had a then current diagnosis of an anxiety disorder. With regards to research
on depression, most of the research conducted focus on studying this disorder in
selected small groups of people. For example, prevalence rate of depression was found
to be 25.1% among male migrant workers living in the UAE (Al-Maskari et al., 2011),
6-22% among medical residents in the country (Abdulrahman, Farooq, Al Kharmiri,
Al Marzooqi, & Carrick, 2018), 10% (post-partum depression) among women in
Sharjah (Hamdan & Tamim, 2011), 17.6% among patients with multiple sclerosis
(Alsaadi et al., 2017), 63.3% among resident doctors working for Dubai Health
Authority (Monsef et al., 2015), and 22.2% among university students (Mellal,
Albluwe, & Al-Ashkar, 2014). Monsef et al. (2015) also reported a prevalence rate of
57.4% for anxiety among resident doctors.
1.1.5 Epigenetics
Humans are more alike than different. We are genetically identical in
approximately 99% of our genomes, with the 1% difference seen in the form of copy
number variations (CNVs), single nucleotide polymorphisms (SNPs) and variation in
the number of tandem repeats (Venter et al., 2001). There are several gene x
environment (G x E) models that have been used to explain the role of both genes and
environment in the development of both depression and anxiety. Of interest is a model
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of epigenetics. Epigenetics can be described as the interaction of our genes with our
developmental biology, which results in “experience-dependent alteration of
epigenetic marks” (Heim & Binder, 2012).. Recent focus of scientific literature on
epigenetics shows how different stressors can change the way our genes are expressed,
without actually changing the DNA. It has been suggested that environmental factors,
such as stress, can affect the epigenetic mechanisms, which in turn may play a role in
how these environmental factors contribute towards the development of ADs. These
mechanisms have the ability to manipulate or alter an organism’s phenotype, and are
controlled by chromatic remodeling, DNA methylation, and non-coding RNAs (Nieto,
Patriquin, Nielsen, & Kosten, 2016).
Epigenetic mechanisms can occur at any time in one’s life. In a remarkable
study conducted by McGowan et al. (2009), it was found that childhood abuse induces
change in the hypothalamic-pituitary-adrenal (HPA) stress responses and increases the
risk of suicide. Furthermore, findings from animal studies suggest a possibility for
passing on epigenetic patterns to offspring through multiple mechanisms (Babenko,
Kovalchuk, & Metz, 2015). In fact, this has been seen in human studies as well, with
prenatal maternal anxiety causing methylation of specific genes in the child (Hompes
et al., 2013). Babenko, Kovalchuk, & Metz (2015) proposed that epigenetic alterations
caused by prenatal stress, and passed on to offspring, can be considered a powerful
influencer of mental health in later stages of the child’s life, with possible increased
risk of developing mental health disorders such as depression, anxiety and even
schizophrenia.
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1.2 Statement of Purpose
The purpose of this research is to study the expression of various genes
associated with depression and ADs among depressed individuals, in an attempt to
identify genetic risk factors in developing depression, and anxiety as a comorbidity.
The genes chosen to be studied are PPARGC1A, CAMKMT, SLC6A4, MAOA and
HSD11B1. To the knowledge of the researcher, no such study has been done using the
residing population of the United Arab Emirates.
1.3 Literature Review
Genetics play an important role in the formulation of psychiatric disorders. If
a group of individuals are exposed to similar adverse life-events, not everyone will
develop a similar (or any) psychiatric illness. This is because genetics are at play with
how environmental stressors are perceived by the individual, making some more
vulnerable to develop psychiatric illnesses than others. For example, McGloin and
Widom (2001) found that 48% of children who underwent childhood abuse and neglect
did not meet the criteria for a psychiatric disorder.
In the past decade, many researchers have turned toward identifying genetic
risk factors associated with various psychiatric conditions, including depression. One
such gene is the SLC6A4, which codes for the serotonin transporter. One of the regions
of this gene is the serotonin transporter promoter polymorphism, 5-HTTLPR. This
polymorphic region has been found to be strongly associated with neuroticism as a
personality trait, which is characterized by depression and anxiety along with other
negative emotions (Lesch et al., 1996; Sen, Burmeister, & Ghosh, 2004), as well as
with the Anxiety factor as measured by Cattell’s 16PF personality inventory (Lesch et
al., 1996). It has also been found to moderate the relationship between stress and
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depression (Karg, Burmeister, Shedden, & Sen, 2011), with individuals with certain
allele(s) of this gene being more susceptible to developing and reporting a depressive
disorder in response to stressful life events as well as childhood maltreatment (Caspi
et al., 2003).
A genome-wide association analysis, carried out by Hettema et al. (2011), on
fear-related behaviors in mice and data collected from the Virginia Adult Twin Study
of Psychiatric and Substance Use Disorders (VATSPSUD) highlighted the role of the
PPARGC1A gene as a potential susceptibility gene for anxiety-related disorders out of
a list of 52 novel candidate genes. The authors suggest that studying phenotypes related
to neuroticism, as a personality trait, in a coordinated manner might be a strong
approach towards identifying potential genes related to ADs. This is because twin
studies indicate that the genetic factors underlying neuroticism are related to, or
overlap with, those that increase susceptibility to various internalizing psychiatric
symptoms and disorders, such as depression and anxiety. Since Hettema et al. (2011)
claim to be the first to suggest the association of PPARGC1A with psychiatric
phenotypes, they call for future replication studies to demonstrate this link. In another
study, the PPARGC1A was studied as a potential susceptibility gene for depression but
was found to be unassociated with the disorder during follow-up (Schosser et al.,
2011).
In one of the largest and most comprehensive genetic studies, carried out by
Otowa et al. (2016) on primary ADs, it was found that the CAMKMT gene (along with
two other genes) has a significant association with anxiety-phenotypes in a large
sample of European ancestry. In animal studies, the CAMKMT gene has been found
to play an essential role in the proper functioning of the adult mouse brain, along with
normal body growth and somatosensory development (Haziza et al., 2015).
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The levels of the monoamine neurotransmitter in the brain is to a large extent
regulated by the monoamine oxidase A (MAOA). The MAOA processes monoamine
transmitters, serotonin, norepinephrine and dopamine (Naoi, Maruyama, & ShamotoNagai, 2008). Serotonin is known to regulate mood in humans. In fact, an effective
class of drugs used for the treatment of depression are the MAOA inhibitors
(Dannlowski et al., 2009). Dysregulation of the monoamine oxidase A (MAOA) gene
has been associated with depression among females (Melas et al., 2013). It has also
been shown to be significantly associated with PD (Deckert et al., 1999; Maron et al.,
2005) and panic attack phenotype (Samochowiec et al., 2004) in females. In a study
carried out by Dannlowski et al. (2009), it was observed that carriers of the higher
active MAOA u-VNTR (upstream variable-number tandem repeat) alleles portrayed a
reduction in the amygdala-prefrontal cortex connectivity, which was shown to be
significantly associated with acute major depression. A similar significant association
between MAOA u-VNTR and MDD, especially among females, was also found in
other studies (Schulze et al., 2000; Yu et al., 2005)
In an unpublished work conducted in the University of Edinburgh, it was found
that the gene HSD11B1 may be associated with anxiety (Frenken, 2012). The 11betahydroxysteroid dehydrogenase Type 1 enzyme, which is associated with the HSD11B1
gene, is responsible for the conversion of cortisone into cortisol (Devang et al., 2017).
Cortisol is a “corticosteroid hormone … (that is) secreted into the bloodstream … in
response to adrenocorticotrophis hormone (ACTH) … especially in response to stress
or injury” (Colman, 2015). The amount of cortisol in body fluids such as blood, saliva
or urine is often used as a measure of stress in a person. Prolonged threat perception
among anxious individuals may cause their biological stress response system to reduce
the secretion of cortisol during the morning period (Miller, Chen, & Zhou, 2007;
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O’Donovan et al., 2010). HSD11B1 has previously been linked to health problems
such as insulin resistance, obesity, metabolic syndrome and diabetes. A specific
polymorphism of this gene – rs12086634, has also been shown to be positively
associated with polycystic ovary syndrome (Devang et al., 2018). In another study, the
gene was found to be associated with Alzheimer’s disease (de Quervain, 2003).
1.4 Research Hypothesis
Based on past research findings, the following hypotheses were set for this
study:
1. The expression of all selected genes is higher among the depressed-group.
2. Expression of MAOA is higher among females in the depressed-group.
A higher expression of PPARGC1A and HSD11B1 will provide confirmatory
evidence to its association with psychiatric phenotypes.
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Chapter 2: Methods
2.1 Participants
Sixty participants were recruited. Thirty participants between the age range of
18-65 were recruited from the outpatient Psychiatric clinic at Al Ain Hospital, Al Ain,
for the depressed-group. These participants had a current diagnosis of either MDD,
dysthymia or adjustment disorder with depressed features given by a psychiatrist using
ICD-10 criteria. Current depressive episode was confirmed using the Beck Depression
Inventory - II (BDI-II). Thirty healthy controls between the age range of 18-65 were
recruited from UAE University. The mean age of the depressed group was 40.3 and
that of the control group was 26.5. Participants in the control-group were excluded if
they scored above 13 on the BDI-II or above 9 on the PHQ-9. Participants in the
depressed-group were excluded if they had (i) comorbid psychotic features, (ii)
comorbid psychiatric disorders such as schizophrenia or personality disorders, or (iii)
current substance abuse.
All participants were required to read and sign the informed consent sheet prior
to participating in the study. They were also required to complete the Patient Health
Questionnaire – 9 (PHQ-9) along with the BDI-II before blood samples were collected.
Ethical approval for the study was provided by the research committees at UAE
University and Al Ain Hospital.
2.2 Assessments
The Beck Depression Inventory and Patient Health Questionnaire were chosen
for this study because its Arabic versions have been validated and found to be reliable
(West, 1985; AlHadi et al., 2017). The Patient Health Questionnaire - 9 (PHQ-9) is a
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depression module and is a self-administered version of the PRIME-MD diagnostic
instrument for common mental disorders (Kroenke, Spitzer, & Williams, 2001). The
BDI-II is a 21-item self-report multiple-choice inventory that takes approximately 10
minutes to complete. It is a widely used tool to indicate the severity of depression,
available in several languages, and appropriate for use by individuals from 13-80 years
of age. The items on this scale are rated on a 4-point scale, with a maximum total score
of 63 (Beck, Steer & Brown, 1996). The level of depression based on raw scores for
this scale, as provided by the BDI-II Manual is shown is Table 2.

Table 2: BDI-II Scores Interpretation
Raw Scores

Depression Severity

0-13

Indicates minimal depression

14-19

Indicates mild depression

20-28

Indicates moderate depression

29-63

Indicates severe depression

2.3 Blood Sampling
About 2.5 ml of blood sample was collected from each participant in a
PAXgene collection-tube provided by Qiagen. These samples were stored in 4°C
before extraction. The analysis of all blood samples was carried out at the Behavioral
Neuroscience Lab at UAE University.
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2.4 RNA Extraction
RNA extraction for all blood samples was done using the PAXgene Blood
RNA Kit provided by PreAnalytiX (Qiagen) (Ref #762164).
All blood samples were centrifuged at 5,000 RCF for 10 minutes, after which
supernatant was decanted. The remaining pellet was dissolved in RNase free water,
and centrifuged for another 10 minutes at 5,000 RCF. Resulting supernatant was
discarded and pellet was dissolved in buffer. The entire solution was transferred to a
1.5ml microcentrifuge tube. To this, proteinase K and binding buffer were added and
the solution was incubated at 55°C for 10 minutes. The entire lysate was transferred to
a shredder column and centrifuged for 3 minutes at 20,000 RCF. The resulting
supernatant was transferred to a microcentrifuge tube. Ethanol was added and mixed
well, and samples were centrifuged for 2 seconds at 1,000 RCF. 700ul of each sample
was transferred to a spin column and centrifuged for 1 minute at 20,000 RCF, after
which the old processing tube was replaced with a new one. The rest of the sample
was transferred to the spin column, to which buffer BR3 was added. After
centrifugation, DNase stock solution and Buffer RDD was added. After incubation,
Buffer BR3 was added again and samples were centrifuged for 1 minute at 20,000
RCF. Samples were then washed and eluted.
Once RNA was extracted, qualitative and quantitative reading for all samples
was recorded using a spectrophotometer.
2.5 Primers Design
Primers for all the genes were designed using the TaqMan Assays and Arrays
tool provided by www.thermofisher.com.
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2.6 Conversion of RNA to cDNA
The extracted RNA was converted to single-strand cDNA using Thermo Fisher
Scientific High-Capacity cDNA Reverse Transcription Kit (Ref #4368814).
cDNA reaction mixture of 20ul was prepared for each reaction using 2ul 10X
RT buffer, 0.8ul 25X dNTP mix, 2ul 10X RT Random Primers, 1ul RT enzyme, and
RNA sample with nuclease-free water. The mixture for all samples were loaded on a
96-well plate for RT-PCR.
2.7 Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR)
RT-PCR was carried out using the Thermal Cycler provided by Thermo Fisher
Scientific. The following conditions were set up for the plate:
i.

Step 1 at 25°C for 10 minutes,

ii.

Step 2 at 37°C for 120 minutes,

iii.

Step 3 at 85°C for 5 minutes, and

iv.

Step 4 at 4°C.

2.8 Quantitative Real Time – Polymerase Chain Reaction (qRT-PCR)
The QuantStudio Real-Time PCR by Thermo Fisher Scientific was used to run
the qRT-PCR. A mixture of 10ul was prepared for each reaction using 8ul of master
mix containing gene primers and 2ul of 10ng cDNA for each sample, and loaded on a
96-well plate. The following conditions were set-up for the plate:
i.

UNG incubation at 50°C for 2 minutes,

ii.

Polymerase activation at 95°C for 2 minutes,

iii.

PCR denature cycle at 95°C for 3 seconds, and

iv.

PCR anneal cycle at 60°C for 30 seconds.
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2.9 Statistical Analysis
The Statistical Package for Social Sciences was used for comparative and
descriptive analysis of the data.
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Chapter 3: Results

The purpose of this study is to explore the genetic biomarkers associated with
depression and anxiety disorders in a depressed population by comparing them with a
normal (non-depressed) control sample. It was hypothesized that all selected genes
will be expressed more in the depressed population. In order to examine the research
hypothesis, one sample was excluded from the study based on quantitative analysis of
RNA, and fifty-nine samples were used for consequent RT-PCR and qRT-PCR.
Results generated from qRT-PCR were subjected to gene expression analysis using
the QuantStudio Design and Analysis Software (version 1.3.1).
3.1 Profile and Statistics of Respondents
This study involved two groups of UAE residents. The first group included
twenty-nine depressed patients and the second group included 30 non-depressed
controls. The distribution of participants between both groups is shown in Table 3.

Table 3: Descriptive Statistics
Depressed
Gender

Nationality

Control

N

%

N

%

Male

15

51.7%

12

40%

Female

14

48.3%

18

60%

Total

29

100%

30

100%

Emirati

12

41.4%

15

50%

Non-Emirati

17

58.6%

15

50%

Total

29

100%

30

100%
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In order to examine the baseline level of depression for both the groups, the
independent-samples t-test was used (see Table 4). The t-test is a statistical procedure
that assesses for any statistically significant difference between the means of two
groups (Duignan, 2016).

Table 4: Independent Samples t Test for Baseline Depression
Group Statistics
BDI
PHQ-9

Group

N

Mean

SD

t

df

p

Patient

29

31.90

10.76

12.73

57

.00

Control

30

5.53

3.53

Patient

29

14.34

4.61

13.32

57

.00

Control

30

2.40

1.65

3.2 Profile of Extracted RNA
All RNA samples were quantified using a spectrophotometer, and checked for
quality. Purity level and concentration of RNA samples is provided in Table 5 (purity
level within the range of 1.8 – 2.0 is considered to meet criteria for further analysis).
Table 5: Purity and Concentration of RNA Samples
Mean

Mean Purity

Concentration

260/280

260/230

Depressed

149.16

2.04

1.84

Control

140.05

2.04

2.00

3.3 Gene Expression Analysis
Gene expression analysis was carried out by the QuantStudio Design and
Analysis Software. Expression level of the genes, when set against a reference level of
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1.0 is shown in Figure 1. The independent samples t – test was used to check the
significance of difference between the expression levels of the genes (Table 6). No
significant difference in gene expression was found for the nationality or gender
variable within each group, so the data were pooled. The data for expression of MAOA
between males and females for the depressed-group are shown in Table 7.

2.5
2
1.5
1
0.5
0
PPARGC1A

CAMKMT

MAOA
Control

Patient

Figure 1: Gene Expression

SLC6A4

HSD11B1
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Table 6: Independent Samples t Test for Gene Expression
Group Statistics
Group

N

Mean

SD

Mean

t

df

p

0.34

2.39

57

0.02

-0.17

-1.46

57

0.15

-0.98

-1.83

57

0.07

0.07

0.32

57

0.75

-0.40

1.71

57

0.10

Difference
PPARGC1A Depressed
CAMKMT
MAOA
SLC6A4
HSD11B1

29

0.45

0.35

Control

30

0.80

0.70

Depressed

29

1.35

0.52

Control

30

1.18

0.33

Depressed

29

2.05

2.21

Control

30

1.07

1.87

Depressed

29

1.30

0.90

Control

30

1.37

0.85

Depressed

29

1.82

1.18

Control

30

1.42

0.54

Table 7: Independent Samples t Test for MAOA Gender Comparison
Group Statistics
Group

N

Mean

SD

Mean

t

df

p

0.75

20

0.47

Difference
MAOA

Male

15

1.75

1.57

Female

14

2.38

2.77

0.63
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Chapter 4: Discussion
4.1 Findings
The results obtained from the gene expression analysis provide significant
information. Of the five genes selected for analysis, only one of them, i.e. PPARGC1A,
was seen to have a significant difference between the two groups with p<0.05. The
PPARGC1A gene has previously been shown to be related to anxious-phenotypes in a
genome-wide association analysis carried out by Hettema et al. (2011). The results
from the current study show that the expression of PPARGC1A is significantly higher
in the control group as compared to the depressed group. This highlights a novel
importance of this gene in association with depression. The results indicate a possible
protective role that the gene may play against developing depressive disorders.
However, this does not contradict the findings of Hettema et al. (2011) as the sample
chosen for this study was that of depression and not anxiety.
PPARGC1A – peroxisome proliferator-activated receptor gamma coactivator
1-alpha – is a transcriptional coactivator for steroid receptors and nuclear receptors. It
plays an important role in energy metabolism and is known to be involved in the
cellular response to oxidative stress and negative regulation of neuron death. Due to
these roles that the gene plays, it could be the case that higher expression of the gene
protects individuals from developing a depressive disorder and a decrease in the
expression makes them more vulnerable to it. What is especially interesting to note is
that PPARGC1A is found to be responsive to several forms of environmental stressors
including nutritional status and temperature (Puigserver et al., 1998; Scarpulla, 2002)
, making it a good candidate for evidence for the epigenetics model. Previous research
has found elevated levels of this gene to serve as a protective factor for neural cells
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against apoptosis caused by oxidative stress (St-Pierre et al., 2006) and improve
neurological symptoms (Tsunemi et al., 2012). Low levels of PPARGC1A have also
been shown to be associated with Alzheimer’s Disease and memory loss (Sweeney &
Song, 2016). Since depression is known to precede clinical diagnosis of Alzheimer’s
Disease, and have a prevalence of upto 50% in patients with Alzheimer’s Disease, it
is important to study the underlying mechanism of the PPARGC1A to better
understand its role against depressive disorders.
The difference in expression for the other genes are not significant at p=0.05.
This is in contradiction with previous research which have linked these genes to
depressive phenotypes. Additionally, even though the expression of the MAOA gene
has the greatest mean difference (-0.98) between the two groups, the difference is not
statistically significant (p = 0.07). This could be due to the large standard deviation
(2.21 and 1.87) between the individual values among the samples and the highest
standard error mean (0.53) among all the genes. HSD11B1 was linked to anxietyphenotypes in a preliminary study (Frenken, 2012). No confirmatory analysis has been
conducted to confirm this linkage. The mean difference of HSD11B1 expression
among the two groups is -0.40 and is not statistically significant (p = 0.10). This
provides novel information that this gene is not associated with depressive disorders.
However, it does reject the results obtained from the preliminary study as no baseline
of anxiety levels was collected from the participants.
Independent samples t-test was also run for the MAOA gene between both the
genders, but no significant difference was seen (p = 0.47). These results were reported
as it was hypothesized that the MAOA gene will be expressed more among females in
the depressed group as compared to the males.
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4.2 Limitations
This research has confronted several limitations. Firstly, the biggest limitation
faced by this research is the lack of data on current medications taken by the
participants, which may impact the expression of genes, such as long-term use of antidepressants. However, this information was intentionally not collected for the current
study to run a basic association analysis for the genes without having to add
medications as an additional variable.
Secondly, the nationality variable was kept open which may act as a
confounding variable and reduce the significance of the results obtained. Third,
baseline data on anxiety levels was not recorded. Lastly, the small sample size may
have played a role in the overall results. It has been reported that when conducting
research in the field of genetics, a minimum of 5000 cases and 5000 controls would be
necessary to obtain 80% power in the data (Shimada-Sugimoto, Otowa & Hettema,
2015). Since such large samples are extremely difficult to recruit for any single study,
replications of studies are crucial to confirm any genetic associations discovered.
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Chapter 5: Conclusion
This study focused on exploring the expression of genetic bio-markers among
depressed patients by comparing them to a non-depressed control group. Five genes
were selected for analysis. The genes associated with anxiety were selected due to high
comorbidity between depressive and anxiety disorders. Studying these genes among a
depressed population would provide insight on the prevalence of anxiety genes among
depressed individuals, or, the role of such genes in mood disorders.
Among the five genes analyzed, only the PPARGC1A was seen to have a
statistically significant difference in the expression levels between the two groups.
This result highlights the role that PPARGC1A may play in protecting against
depressive disorders.
Contrary to previous research, no other significant differences among gene
expressions between the two groups were observed in the current study.
5.1 Research Implications
The current study is one of very few studies conducted on genetic association
with depression in the region. To the knowledge of the researcher, no such previous
study has been published in the country. The results obtained from the study are thus
novel and significant. Implementing and making proper use of such results however,
will require further research.
Identifying the genes associated with depression can have several implications
in any population. With the rise in genetic testing and the boom in genome-wide
association studies, it has become easier to test individual biomarkers such as genetic
make-up, gene expression, DNA, etc. If depressive genes are identified at a young age,
individuals and mental health professionals, and especially family members, can be
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cautious about environmental stressors and the kind of support and understanding that
is expressed. The results of the current study raise the possibility that PPARGC1A
could be used as a therapeutic agent in the treatment of depression.
Further research is recommended to confirm the results obtained in the current
study. Future studies can focus on the pathways involved in the functioning of
PPARGC1A to understand its role in depressive disorders. It is also recommended to
explore its possible association with the upregulation of key neurotransmitters
associated with depression, such as serotonin and dopamine. It is also recommended
that further research be conducted keeping the nationality variable constant. A larger
sample size can also add significance to future research.
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